^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SIM0235

    i
    Other names: SIM0235, SIM1811-03, SIM-235
    Associations

    News

    Trials
    Company:
    Simcere
    Drug class:
    TNFRSF1B antagonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China (ESMO 2023)
    The preliminary PK and PD results support every 3-week dosing at 40mg/kg as the recommended dose for expansion. The clinical development of SIM1811-03 in combination with immunotherapy is planned.
    Clinical • P1 data • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD14 (CD14 Molecule)
    |
    SIM0235